Forward Ventures

Home Company Team Strategy Criteria Portfolio Portfolio News Submit Your Plan Partner Area Contact



Forward Ventures, founded in 1993, is a leading life-science venture capital firm located in San Diego. Forward has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has invested in over 50 companies since it was founded in 1993 and currently has more than $500 million in capital under management. The most recent fund, Forward V, continues Forward Ventures’ program of life sciences and health care venture investing in companies of all stages of development. Forward invests throughout the United States and will consider select European opportunities.

In addition to the established venture program, the Forward Medical Science Partners (ForMS) fund works in partnership with the pharmaceutical industry.

 

10/04/2012
Takeda to Acquire LigoCyte Pharmaceuticals, Inc.
LigoCyte Press Release
more
09/12/2011
HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
HemaQuest Press Release
more
09/06/2011
Syndax Pharmaceutical’s Positive Phase 2 Data Supports Potential for Entinostat in Advanced Breast Cancer
Syndax Press Release
more
08/17/2011
Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
Syndax Press Release
more
06/16/2011
Tioga Pharmaceuticals Issued Key U.S. Patent for the Use of Asimadoline to Treat D-IBS
Tioga Press Release
more
06/08/2011
Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
Syndax Press Release
more
06/02/2011
Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
Syndax Press Release
more
06/01/2011
FDA Grants Fast Track Designation to Tioga Pharmaceuticals’ Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Tioga Press Release
more
05/02/2011
Affinium Pharmaceuticals, Ltd., Announces Results of AFN-1252 Multiple Ascending Dose Phase I Clinical Trial
Affinium Press Release
more
04/25/2011
HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
HemaQuest Press Release
more
03/31/2011
Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
Syndax Press Release
more
03/01/2011
Syndax Announces Start Of NCI Sponsored Phase 2 Study Of Entinostat In Combination In Triple Negative Breast Cancer
Syndax Press Release
more
12/09/2010
Syndax Pharmaceuticals’ Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
Syndax Press Release
more
12/07/2010
HemaQuest Pharmaceuticals, Inc. Presents Promising Clinical Results at 52nd Annual Meeting of the American Society of Hematology (ASH)
HemaQuest Press Release
more
12/03/2010
HemaQuest Announces Appointment of New Executive Management Team, Company Establishes Headquarters in San Diego
HemaQuest Press Release
more
10/25/2010
Essentialis Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Trial of DCCR
Essentialis Press Release
more
10/12/2010
Affinium Pharmaceuticals, Ltd. Announces the Initiation of an Oral, Multiple-Ascending-Dose Phase I Clinical Trial of AFN-1252, its Novel Anti-staphylococcal Antibiotic
Affinium Press Release
more
08/11/2010
HemaQuest Pharmaceuticals Initiates Phase 2 Clinical Trial in EBV‐Related Malignancies
HemaQuest Press Release
more
08/05/2010
HemaQuest Pharmaceuticals Initiates Phase 2 Clinical Trial in EBV-Related Malignancies
HemaQuest Press Release
more
07/28/2010
Sainsbury’s Becomes First UK Retailer to Install Asteres 24/7 Automated Pharmacy Kiosks
Asteres Press Release
more
07/28/2010
HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
HemaQuest Press Release
more
06/30/2010
Sanofi-aventis To Acquire TargeGen, Inc
TargeGen Press Release
more
06/04/2010
Syndax Pharmaceuticals’ Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
Syndax Press Release
more
06/03/2010
Tioga Pharmaceuticals Begins Phase 3 Trial of Asimadoline in Irritable Bowel Syndrome  
Tioga Press Release
more
05/24/2010
Syndax Pharmaceuticals Inc. to Present Entinostat Data Showing Benefit in Combination in Advanced Breast Cancer at ASCO 
Syndax Press Release
more
04/09/2010
Affinium Pharmaceuticals, Ltd. Announces the Initiation of a Phase I Clinical Trial Using an Optimized Oral Formulation of AFN-1252, its Novel Anti-staphylococcal Antibiotic 
Affinium Press Release
more
04/05/2010
Tioga Pharmaceuticals Receives Special Protocol Assessment Agreement from FDA for Phase 3 Trials of Asimadoline in Irritable Bowel Syndrome 
Tioga Press Release
more
03/11/2010
China's WuXi, a Partner of San Diego's TargeGen, Offers New Model for Drug Development
X-Conomy.com
more
03/31/2010
Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
Syndax Press Release
more
02/17/2010
Tioga Pharmaceuticals, Inc. Raises $18 Million to Fund Phase 3 Clinical Trial in Irritable Bowel Syndrome 
Tioga Press Release
more
12/21/2009
Biotech company has survival skills: Ambit Biosciences overcomes challenges, now has new partner 
San Diego Union Tribune
more
12/18/2009
Ambit Biosciences And Astellas Enter Strategic Partnership To Research, Develop And Commercialize Flt3 Kinase Inhibitors In Multiple Indications
Ambit Biosciences Press Release
more
12/11/2009
Ambit Biosciences Initiates First Phase 2 Clinical Trial Of Ac220 In Acute Myeloid Leukemia
Ambit Biosciences Press Release
more
12/8/2009
HemaQuest Pharmaceuticals Presents Promising Results in Sickle Cell Disease and Beta Thalassemia
HemaQuest Press Release
more
12/7/2009
Ambit Biosciences Corporation Presents Phase I Clinical Results Of Ac220 In Patients With Acute Myeloid Leukemia At Ash Conference
Ambit Biosciences Press Release
more
11/23/2009
Nereus Pharmaceuticals Presents Positive Interim Data from the ADVANCE study, A Randomized Phase 2 Clinical Trial of Plinabulin (NPI-2358) in Non-Small Cell Lung Cancer at the 2009 EORTC-NCI-AACR Conference
Nereus Press Release
more
10/22/2009
TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients
TargeGen Press Release
more
9/18/2009
NovoStent Announces Completion of Enrollment in SAMBA Femoropopliteal Trial
NovoStent Press Release
more
9/1/2009
Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co. Announce Agreement to Develop and Commercialize Asimadoline in Japan
Tioga Press Release
more
8/18/2009
Fine-tuning an anti-cancer drug
Nereus Press Release
more
8/11/2009
Essentialis To Submit Spa For Hypertriglyceridemia
Essentialis Press Release
more
8/5/2009
Asteres Inc. Names Retail Veteran Jim Mastrian to Board of Directors
Asteres Press Release
more
8/4/2009
Asteres Inc. Debuts ScriptCenter 24/7 Automated Pharmacy Services
Asteres Press Release
more
6/9/2009
Asteres Inc. Expands Markets and Management naming Mark de Bruin, CEO
Asteres Press Release
more
6/3/2009
Asteres Inc. Announces Hansen Retirement
Asteres Press Release
more
5/26/2009
HemaQuest Initiates Clinical Trials in Sickle Cell Disease and Beta Thalassemia
HemaQuest Press Release
more
5/18/2009
Essentialis Meets Primary Endpoint In Phase 2b Trial Of DCCR For Treatment Of Hypertriglyceridemia And Is Granted Extensive Patent Coverage In The US
Essentialis Press Release
more
5/14/2009
TargeGen Announces Successful Completion of Patient Enrollment In Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients And Scheduled Presentation of Preliminary Trial Data At EHA Conference in Berlin
TargeGen Press Release
more
3/25/2009
HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations for Therapeutic to Treat Hemoglobin Disorders
HemaQuest Press Release
more
3/23/2009
Nereus Pharmaceuticals Initiates ADVANCE, A Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Nereus Press Release
more





4747 Executive Drive | Suite 700 | San Diego, CA 92121